We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
-1.36%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.32B
AUM Growth
-$280M
(-18%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-15.04%
Top 10 Holdings %
Top 10 Hldgs %
17.04%
Holding
1,626
New
448
Increased
346
Reduced
313
Closed
483
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$9.86M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$9.7M |
| 3 |
CNR
Core Natural Resources Inc
CNR
|
+$8.26M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
+$6.63M |
| 5 |
Oracle
ORCL
|
+$6.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SMAR
Smartsheet Inc.
SMAR
|
+$14M |
| 2 |
HTLF
Heartland Financial USA, Inc.
HTLF
|
+$11.1M |
| 3 |
NVIDIA
NVDA
|
+$9.36M |
| 4 |
Amazon
AMZN
|
+$8.75M |
| 5 |
Netflix
NFLX
|
+$8.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 13.2% |
| 2 | Healthcare | 10.48% |
| 3 | Consumer Discretionary | 9.93% |
| 4 | Financials | 7.26% |
| 5 | Communication Services | 6.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
CorMedix
CRMD
$591M
| $91.2K | 0.01% |
+14,810
| New | +$153K |
|
|
API
1052
Agora
API
$386M
| $90K | 0.01% |
+22,378
| New | +$117K |
|
|
SLRN
1053
DELISTED
ACELYRIN
SLRN
| $89.5K | 0.01% |
36,220
-51,961
| -59% | -$124K |
|
1054
Under Armour
UAA
$2.52B
| $88.6K | 0.01% |
14,178
+998
| +8% | +$7.43K |
|
1055
UWM Holdings
UWMC
$2.26B
| $87.7K | 0.01% |
+16,066
| New | +$97.6K |
|
1056
Voyager Therapeutics
VYGR
$195M
| $87.3K | 0.01% |
25,817
+8,017
| +45% | +$37.5K |
|
|
BORR
1057
Borr Drilling
BORR
$1.28B
| $84.3K | 0.01% |
+38,502
| New | +$116K |
|
1058
FTAI Infrastructure
FIP
$508M
| $82.2K | 0.01% |
+18,149
| New | +$113K |
|
1059
Vermilion Energy
VET
$1.75B
| $82K | 0.01% |
+10,121
| New | +$90.4K |
|
|
AUNA
1060
Auna
AUNA
$390M
| $80K | 0.01% |
+11,250
| New | +$87.7K |
|
1061
American Express Global Business Travel
GBTG
$4.94B
| $77.9K | 0.01% |
+10,736
| New | +$90.6K |
|
1062
Cytek Biosciences
CTKB
$606M
| $77K | 0.01% |
19,200
-9,680
| -34% | -$50.2K |
|
1063
Cullinan Oncology
CGEM
$1.18B
| $76.9K | 0.01% |
+10,152
| New | +$97.4K |
|
1064
Aveanna Healthcare
AVAH
$2.06B
| $74.9K | 0.01% |
+13,828
| New | +$65.2K |
|
1065
Stereotaxis
STXS
$143M
| $73.8K | 0.01% |
41,959
+9,789
| +30% | +$20.9K |
|
1066
Neuronetics
STIM
$151M
| $73.6K | 0.01% |
+20,010
| New | +$73.1K |
|
1067
4D Molecular Therapeutics
FDMT
$582M
| $72.7K | 0.01% |
+22,500
| New | +$106K |
|
1068
Resources Connection
RGP
$145M
| $72.6K | 0.01% |
+11,100
| New | +$86.2K |
|
|
SVCO
1069
Silvaco Group
SVCO
$250M
| $71.8K | 0.01% |
+15,752
| New | +$108K |
|
|
TBI
1070
Trueblue
TBI
$323M
| $71.7K | 0.01% |
13,500
+3,000
| +29% | +$20.5K |
|
|
SLSR
1071
Solaris Resources
SLSR
$1.38B
| $69.7K | 0.01% |
20,575
-3,753
| -15% | -$13.1K |
|
1072
Clarus
CLAR
$145M
| $69K | 0.01% |
18,400
+2,200
| +14% | +$9.87K |
|
1073
FreightCar America
RAIL
$259M
| $68.9K | 0.01% |
+12,468
| New | +$118K |
|
1074
Gain Therapeutics
GANX
$75.5M
| $68.4K | 0.01% |
35,820
| – | – |
|
1075
Crexendo
CXDO
$209M
| $66K | 0.01% |
13,543
-3,100
| -19% | -$18.2K |
|
Similar funds
PFBT
SP
HCS
SPC
GPCM
MCM
CC
MB
Prelude Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Prelude Capital Management held 1,626 positions worth $1.32B, down 18% from $1.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Prelude Capital Management withdrew a net $198M in Q1 2025, closing 483 positions and reducing 313 holdings. Its most notable exit was Smartsheet Inc., an estimated $14M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, down from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Prelude Capital Management opened a new position in Intra-Cellular Therapies Inc. worth $10.4M.
- Prelude Capital Management's largest Q1 2025 buy was Intra-Cellular Therapies Inc.: 79,142 shares worth $10.4M.
- Prelude Capital Management added most to Alphabet (Google) Class A in Q1 2025, an estimated $9.7M increase.
- Prelude Capital Management's biggest Q1 2025 reduction was NVIDIA, cutting an estimated $9.36M.
- Prelude Capital Management fully exited Smartsheet Inc. in Q1 2025, selling an estimated $14M.
- Prelude Capital Management's ten largest holdings make up 17% of its $1.32B portfolio in Q1 2025.
- Prelude Capital Management opened 448 new positions and closed 483 in Q1 2025.
- Prelude Capital Management's portfolio value fell 18% quarter-over-quarter to $1.32B.
Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.